Connor, Clark & Lunn Investment Management (CC&L)
NVO

Connor, Clark & Lunn Investment Management (CC&L)’s Novo Nordisk NVO Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.58M Buy
95,475
+48,552
+103% +$2.09M 0.01% 760
2026
Q1 		$1.72M Buy
46,923
+14,002
+43% +$663K ﹤0.01% 1006
2025
Q4 		$1.68M Sell
32,921
-2,337
-7% -$120K ﹤0.01% 968
2025
Q3 		$1.96M Buy
35,258
+14,937
+74% +$874K 0.01% 857
2025
Q2 		$1.4M Sell
20,321
-3,538
-15% -$241K ﹤0.01% 962
2025
Q1 		$1.66M Sell
23,859
-33,618
-58% -$2.78M 0.01% 784
2024
Q4 		$4.94M Sell
57,477
-6,435
-10% -$696K 0.02% 485
2024
Q3 		$7.61M Sell
63,912
-91,815
-59% -$12.2M 0.04% 338
2024
Q2 		$22.2M Sell
155,727
-29,398
-16% -$3.9M 0.09% 175
2024
Q1 		$23.8M Sell
185,125
-168,644
-48% -$20.1M 0.1% 179
2023
Q4 		$36.6M Buy
353,769
+281,333
+388% +$27.8M 0.17% 115
2023
Q3 		$6.59M Sell
72,436
-167,338
-70% -$14.7M 0.03% 330
2023
Q2 		$19.4M Buy
239,774
+214,172
+837% +$17.5M 0.1% 159
2023
Q1 		$2.04M Sell
25,602
-369,260
-94% -$26.2M 0.01% 547
2022
Q4 		$26.7M Buy
394,862
+4,986
+1% +$292K 0.15% 111
2022
Q3 		$19.4M Buy
389,876
+118,604
+44% +$6.35M 0.13% 123
2022
Q2 		$15.1M Buy
271,272
+69,214
+34% +$3.84M 0.09% 160
2022
Q1 		$11.2M Buy
202,058
+19,600
+11% +$1.01M 0.06% 213
2021
Q4 		$10.2M Buy
182,458
+4,972
+3% +$269K 0.05% 240
2021
Q3 		$8.52M Buy
177,486
+107,272
+153% +$5.19M 0.04% 267
2021
Q2 		$2.94M Buy
+70,214
New +$2.72M 0.01% 462
2020
Q3 		– Sell
-238,240
Closed -$7.8M – 1061
2020
Q2 		$7.8M Sell
238,240
-679,370
-74% -$21.7M 0.06% 230
2020
Q1 		$27.6M Sell
917,610
-270,800
-23% -$8.06M 0.25% 81
2019
Q4 		$34.4M Buy
1,188,410
+667,350
+128% +$18.5M 0.24% 89
2019
Q3 		$13.5M Buy
521,060
+104,100
+25% +$2.63M 0.09% 147
2019
Q2 		$10.6M Sell
416,960
-260,250
-38% -$6.43M 0.07% 187
2019
Q1 		$17.7M Buy
677,210
+403,000
+147% +$9.9M 0.12% 132
2018
Q4 		$6.32M Sell
274,210
-411,238
-60% -$9.14M 0.04% 234
2018
Q3 		$16.2M Buy
+685,448
New +$16.7M 0.09% 157
2018
Q1 		– Sell
-59,200
Closed -$1.59M – 777
2017
Q4 		$1.59M Buy
+59,200
New +$1.51M 0.01% 458
2017
Q2 		– Sell
-344,226
Closed -$5.9M – 903
2017
Q1 		$5.9M Buy
+344,226
New +$5.99M 0.04% 225

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s NVO Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Novo Nordisk (NVO) stake by 103% in Q2 2026, buying an estimated $2.09M and bringing the position to 95,475 shares worth $4.58M. The position accounts for 0.01% of the portfolio, ranked #760.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in NVO in Q1 2017 and has held it in 31 quarters since. The position peaked at $36.6M in Q4 2023. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 95,475 shares of Novo Nordisk worth $4.58M as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) bought 48,552 Novo Nordisk shares in Q2 2026, an estimated $2.09M.
  • Novo Nordisk made up 0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #760 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Novo Nordisk in Q1 2017 and has held it in 31 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Novo Nordisk position peaked at $36.6M in Q4 2023.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.